| Stock Name | 同源康医药－Ｂ |
|---|---|
| Stock Code | 02410 |
| Company Full Name | 同源康医药－Ｂ |
| Industry | 醫療保健 |
| Principal Activities | 公司是一家臨床階段的生物制藥公司，致力于發現、收購、開發差異化靶向治療并對其進行商業化，以滿足癌癥治療中亟待滿足的醫療需求。 |
| Listing Date | 2024-08-20 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國浙江省湖州市長興經濟開發區明珠路1278號長興世貿大廈A座14層1403-2室 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.tykmedicines.com/ |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 12.10 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 35.5% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 57,934,800 |
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 500 | HK$ 6,050 |
| 2 lots | 1,000 | HK$ 12,100 |
| 3 lots | 1,500 | HK$ 18,150 |
| 4 lots | 2,000 | HK$ 24,200 |
| 5 lots | 2,500 | HK$ 30,250 |
| 6 lots | 3,000 | HK$ 36,300 |
| 7 lots | 3,500 | HK$ 42,350 |
| 8 lots | 4,000 | HK$ 48,400 |
| 9 lots | 4,500 | HK$ 54,450 |
| 10 lots | 5,000 | HK$ 60,500 |
| 12 lots | 6,000 | HK$ 72,600 |
| 14 lots | 7,000 | HK$ 84,700 |
| 16 lots | 8,000 | HK$ 96,800 |
| 18 lots | 9,000 | HK$ 108,900 |
| 20 lots | 10,000 | HK$ 121,000 |
| 30 lots | 15,000 | HK$ 181,500 |
| 40 lots | 20,000 | HK$ 242,000 |
| 50 lots | 25,000 | HK$ 302,500 |
| 60 lots | 30,000 | HK$ 363,000 |
| 100 lots | 50,000 | HK$ 605,000 |
| 120 lots | 60,000 | HK$ 726,000 |
| 140 lots | 70,000 | HK$ 847,000 |
| 160 lots | 80,000 | HK$ 968,000 |
| 180 lots | 90,000 | HK$ 1,089,000 |
| 200 lots | 100,000 | HK$ 1,210,000 |
| 400 lots | 200,000 | HK$ 2,420,000 |
| 600 lots | 300,000 | HK$ 3,630,000 |
| 800 lots | 400,000 | HK$ 4,840,000 |
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1,000 lots | 500,000 | HK$ 6,050,000 |
| 2,500 lots | 1,250,000 | HK$ 15,125,000 |
| 3,000 lots | 1,500,000 | HK$ 18,150,000 |
| 3,500 lots | 1,750,000 | HK$ 21,175,000 |
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
| First Day Close | HK$ 13.7 |
|---|---|
| First Day Open | HK$ 14.48 |
| First Day Change | 13.22% |
| First Day Volume | 3187500.0 |
| First Day Turnover | 43620800.0 |
| Use of Proceeds | 1、70.0%或約354.4百萬港元將用于核心產品（即TY-9591）的研究、開發 及商業化； 2、20.0%或約101.3百萬港元將用于其他候選產品的研發； 3、3.0%或約15.2百萬港元將用于潛在的戰略收購、投資、許可或合作機會； 4、7.0%或約35.4百萬港元將用于營運資金及其他一般公司用途。 |
|---|
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 长兴兴长产业投资合伙企业(有限合伙) | 205,700,000 HKD | — | 35.51% | — | 6 months | 2025-02-20 |
| Chairman | 吳豫生 |
|---|---|
| Company Secretary | 黃詠儀 |
| Major Shareholders & Holdings | 鄭州泰基鴻諾醫藥股份有限公司(26.97%),長興利源企業管理合伙企業(有限合伙)(6.11%) |
|---|
Market Sentiment
The IPO of 同源康医药－Ｂ saw a modest oversubscription ratio of 2.29x, indicating subdued demand. The overall hit rate was 66.63%, meaning approximately two-thirds of valid applications were accepted, which is relatively high compared to typical Hong Kong IPOs. This reflects a less competitive environment. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Tier Analysis
The last A-tier applicant (400,000 shares applied) received an expected allocation of only 0.33 lots, while the first B-tier applicant (500,000 shares) received exactly 1.0 lot. This sharp drop suggests an inefficient cliff-edge effect, making the A-tail highly unfavorable for small institutional or large retail investors. Broker fee per allocated lot would be disproportionately high for A-tail applicants compared to B-head. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Demographics
Demographic data for this IPO is unavailable, with recorded totals and regional percentages all showing zero. Without information on mainland China participation or geographic distribution, no meaningful demographic analysis can be performed. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
